This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
by Zacks Equity Research
MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
by Zacks Equity Research
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
Stock Market News for Nov 4, 2025
by Zacks Equity Research
Wall Street ended mostly higher, with the Nasdaq and the S&P 500 finishing in positive territory, as investors once again flocked to artificial intelligence (AI) stocks following the announcement of a spate of new deals.
Why Merck (MRK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
by Sundeep Ganoria
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
by Zacks Equity Research
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
by Kinjel Shah
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
by Kinjel Shah
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
by Ahan Chakraborty
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
by Kinjel Shah
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
by Kanishka Das
MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
by Sundeep Ganoria
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
by Zacks Equity Research
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
Will BMY's Growth Portfolio Drive Third-Quarter Results?
by Ekta Bagri
Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $86.32, moving +1.8% from the previous trading session.
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
by Sundeep Ganoria
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
by Kanishka Das
Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.